Compare Multi Makmur Lemindo Tbk. (PIPA) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Multi Makmur Lemindo Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Multi Makmur Lemindo Tbk. trades at Rp200 (market cap 692.07B, 152.5M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Multi Makmur Lemindo Tbk. is far larger — about 6.6× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| PIPA | SCPI | |
|---|---|---|
Market Cap | 692.07B | 104.4B |
Volume | 152.5M | — |
Lot | 1.53M | — |
Turnover | 30.51B | — |
Average Price | 200.07 | — |
Value | 30.51B | — |
Indicative Equilibrium Price | 200 | — |
Indicative Equilibrium Volume | 16.19K | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Multi Makmur Lemindo Tbk.
PT Multi Makmur Lemindo Tbk (the Company) was established based on Notarial Deed No. 66 dated January 11, 2012 of Deni Nugraha, S.E., S.H., M.Kn., notary in Tangerang. The Company started its commercial operations in 2005.
Read more on PIPA →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
